Pfizer, AbbVie settle global IP for Humira biosimilar, paving way for European launch

By on    Pharma Industry News  

Pfizer, AbbVie settle global IP for Humira biosimilar, paving way for European launch

In a significant step towards expanding biosimilar access, Pfizer and AbbVie have resolved all global intellectual property disputes concerning Pfizer’s proposed biosimilar to AbbVie’s blockbuster rheumatoid arthritis drug, Humira (adalimumab). This agreement marks a major milestone in Pfizer’s mission to broaden its portfolio of biosimilar medications, as it acquires a non-exclusive patent license to market […]

Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas

By on    Pharma Industry News  

Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas

In a significant advancement for biopharmaceuticals, Novartis’ division Sandoz has secured approval from the European Commission (EC) for Hyrimoz (adalimumab), a biosimilar to AbbVie’s Humira. This approval encompasses all indications of the reference drug, including treatment for rheumatoid arthritis, Crohn’s disease, plaque psoriasis, uveitis, and ulcerative colitis, marking a pivotal step in broadening access to […]